

Title: Adoption of Rimegepant in Denmark: A Register-Based Study on Uptake, Prescribing Patterns and Initiator Characteristics

Journal: The Journal of Headache and Pain

Authors' names and affiliations: Lanfranco Pellesi¹, Thien Phu Do^{2,3,4}, Martin Thomsen Ernst¹, Jesper Hallas¹, Anton Pottegård¹.

¹ Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.

² Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

³ Department of Neurology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.

⁴ Danish Knowledge Center on Headache Disorders, Glostrup, Denmark.

Correspondence:

Lanfranco Pellesi, Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark.

Email: lpellesi@health.sdu.dk.

Supplementary Table 1. Prevalence of acute medication overuse among rimegepant users for the acute treatment of migraine.

	One or the other criteria	Use of ≥ 10 DDD of triptans	Use of ≥ 10 DDD of opioids	Use of ≥ 15 DDD of NSAIDs	Use of ≥ 15 DDD of paracetamol
Days relative to index date: -180 to -90	1735 (66%)	1411 (53%)	99 (3.7%)	356 (13%)	486 (18%)
Days relative to index date: -150 to -60	1722 (65%)	1402 (53%)	99 (3.7%)	365 (14%)	492 (19%)
Days relative to index date: -120 to -30	1734 (66%)	1423 (54%)	87 (3.3%)	352 (13%)	501 (19%)
Days relative to index date: -90 to 0	1829 (69%)	1493 (57%)	91 (3.4%)	396 (15%)	502 (19%)
Days relative to index date: -60 to 30	1730 (65%)	1398 (53%)	96 (3.6%)	359 (14%)	467 (18%)
Days relative to index date: -30 to 60	1666 (63%)	1319 (50%)	99 (3.7%)	365 (14%)	462 (17%)
Days relative to index date: 0 to 90	1610 (61%)	1227 (46%)	98 (3.7%)	363 (14%)	495 (19%)
Days relative to index date: 30 to 120	1485 (56%)	1126 (43%)	82 (3.1%)	303 (11%)	458 (17%)
Days relative to index date: 60 to 150	1442 (55%)	1082 (41%)	80 (3.0%)	298 (11%)	440 (17%)
Days relative to index date: 90 to 180	1354 (51%)	1004 (38%)	71 (2.7%)	288 (11%)	421 (16%)

DDD: Defined daily dose; NSAID: nonsteroidal anti-inflammatory drug.

Supplementary Table 2. Prevalence of acute medication overuse among rimegepant users for the preventive treatment of migraine.

	One or the other criteria	Use of ≥ 10 DDD of triptans	Use of ≥ 10 DDD of opioids	Use of ≥ 15 DDD of NSAIDs	Use of ≥ 15 DDD of paracetamol
Days relative to index date: -180 to -90	106 (79%)	89 (66%)	8 (5.9%)	26 (19%)	25 (19%)
Days relative to index date: -150 to -60	98 (73%)	80 (59%)	8 (5.9%)	30 (22%)	24 (18%)
Days relative to index date: -120 to -30	100 (74%)	81 (60%)	9 (6.7%)	27 (20%)	25 (19%)
Days relative to index date: -90 to 0	100 (74%)	89 (66%)	10 (7.4%)	18 (13%)	24 (18%)
Days relative to index date: -60 to 30	97 (72%)	84 (62%)	9 (6.7%)	15 (11%)	25 (19%)
Days relative to index date: -30 to 60	93 (69%)	79 (59%)	9 (6.7%)	21 (16%)	24 (18%)
Days relative to index date: 0 to 90	89 (66%)	72 (53%)	8 (5.9%)	25 (19%)	26 (19%)
Days relative to index date: 30 to 120	86 (64%)	71 (53%)	6 (4.4%)	25 (19%)	23 (17%)
Days relative to index date: 60 to 150	75 (56%)	62 (46%)	7 (5.2%)	20 (15%)	15 (11%)
Days relative to index date: 90 to 180	71 (53%)	60 (44%)	7 (5.2%)	16 (12%)	18 (13%)

DDD: Defined daily dose; NSAID: nonsteroidal anti-inflammatory drug.

Figure S1. Age distribution in quarterly incidence rate (per 10 000 person-years) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S2. Gender distribution in quarterly incidence rate (per 10 000 person-years) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S3. Age distribution in prevalence proportion (per 10 000 inhabitants) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S4. Gender distribution in prevalence proportion (per 10 000 inhabitants) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S5. Age distribution in total defined daily doses (DDDs; in thousands) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S6. Gender distribution in total defined daily doses (DDDs; in thousands) of rimegepant for the period from 1 October 2022 to 30 December 2024 in Denmark.




Figure S7. Retention of rimegepant among early initiators (2022-2023) by age over a 360-day period, under the assumption of a 30-day duration of prescription. Data were analyzed using the proportion of patients covered technique.




Figure S8. Retention of rimegepant among early initiators (2022-2023) by sex over a 360-day period, under the assumption of a 30-day duration of prescription.




Figure S9. Retention of rimegepant among early initiators (2022-2023) by rimegepant utilization (acute vs. preventive indication) over a 360-day period, under the assumption of a 30-day duration of prescription.

